FDA takes control of cannabinoid products with mandatory testing and age-gating rules.
S. 3474 — Cannabinoid Safety and Regulation Act · Filed by Ron Wyden (D-OR) · 2 cosponsors · Introduced Dec 15, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill establishes federal FDA regulation of cannabinoid products (including hemp-derived and cannabis-derived products containing THC or CBD). It requires manufacturers to register facilities, label products with potency and safety information, comply with manufacturing standards, and submit to testing for contaminants. States retain authority to set stricter rules, but cannot impose labeling requirements different from federal standards. The bill does not legalize cannabis but creates a regulatory framework similar to dietary supplements or food additives.
Why we flagged it
The bill's operative mechanism is establishing federal safety and labeling standards for cannabinoid products under FDA authority. It is not a legalization bill, tax measure, or industry carve-out—it is a straightforward regulatory framework creating product safety requirements.
What the text implies
- Section 1104(a)(1) requires remote-sales age-verification regulations within 3 years, but does not specify enforcement mechanism or penalties for non-compliance, creating potential gaps in online sales enforcement.
- Section 1102(8)–(10) prohibit gummy shapes and child-appealing packaging, but enforcement depends on FDA resources and state cooperation; violations may be difficult to detect in secondary markets.
- Section 1104(j) permits FDA to regulate synthetic and semi-synthetic cannabinoids, but the bill does not define 'safety' thresholds for novel cannabinoids, potentially creating regulatory uncertainty for emerging products.
- Section 1109(1)(C) prohibits states from blocking interstate transport of compliant cannabinoid products, which may override state-level prohibition or licensing regimes and create conflict with state law.
- The bill does not address banking or tax treatment of cannabinoid businesses, leaving them subject to federal money-laundering and tax code restrictions despite state-legal status.
Section numbers refer to the bill text the analysis read — linked under Primary records below.
Who it affects
Ordinary consumers gain mandatory safety testing, potency labeling, contamination screening, and age-gating protections—reducing exposure to mislabeled, contaminated, or high-dose products. The regulatory framework mirrors FDA oversight of other consumer products. Manufacturers face compliance costs, but these are passed through pricing and do not eliminate market access.
Who stands to gain
- cannabinoid product manufacturers and distributors (market access and regulatory clarity)
- testing laboratories (mandatory testing requirement)
- packaging and labeling suppliers (new compliance requirements)
- age-verification service providers (online sales verification mandate)
Named in the bill
FDA (Food and Drug Administration), DEA (Drug Enforcement Administration), USDA (Department of Agriculture), State governments, Indian Tribes, Cannabinoid product manufacturers, Testing laboratories, ASTM International, AOAC International
Where it stands
2 cosponsors: 2 Democrats.
- Dec 15, 2025 — Introduced · Congress.gov: “Introduced in Senate”
- Dec 15, 2025 — Referred to Senate Committee on Health, Education, Labor, and Pensions · Congress.gov: “Read twice and referred to the Committee on Health, Education, Labor, and Pensions”
Dates and quoted wording are Congress.gov's action record; the timeline shows status changes, not every procedural step.
Money around this bill
5 lobbying clients named this bill on 6 disclosure filings across 2 quarters, Dec 2025 to Jun 2026. Those filings disclosed $260,000 in lobbying spend. A filing names 5 bills on average, so that figure is what each filing reported, not a share belonging to this bill.
More lobbying clients named this bill than 78% of bills with at least one filing.
Ron Wyden, the sponsor, reported $375,070 in PAC receipts in the 2026 cycle.
- Hemp Beverage Alliance — $100,000 on 2 filings
- Hemp Industry & Farmers of America (hifa) — $50,000 on 1 filing
- American Healthy Alternatives Association (ahaa) — $40,000 on 1 filing
- Edible Brands, LLC — $40,000 on 1 filing
- Students for Sensible Drug Policy — $30,000 on 1 filing
Lobbying Disclosure Act filings through Jul 20, 2026. A filing shows who paid to lobby on a bill it names, not what changed.
How this was measured
Analysis — Quorum's AI read the bill text published by Congress.gov (50,094 characters) on Sep 27, 2026. Section numbers in the findings refer to that text, linked below; transparency and hidden-provision scores are compared against the median of 16,222 analysed bills.
Status and sponsors — Congress.gov's bill record — actions, committee referrals and cosponsors — loaded nightly. The timeline shows status changes, not every procedural action.
Money — Senate Lobbying Disclosure Act filings whose specific-issue field names this bill for quarters ending Dec 2025 to Jun 2026. A filing's amount is reported whole beside the median number of bills a filing names; it is never divided across them. PAC receipts are FEC-reported contributions to the sponsor's candidate committee in the 2026 cycle.
As of — lobbying records through Jul 20, 2026 · page rendered 2026-10-20.
“FDA takes control of cannabinoid products with mandatory testing and age-gating rules.” QuorumCivic. https://share.quorumcivic.app/bill/119/s3474 Report an error
The week in bills
One email, Sunday: what Congress passed, what it changed, and who paid.
One link arrives to confirm the address. It is used for this email and nothing else, and every issue carries an unsubscribe link.